Updates

Explore Medicines360’s latest news and resources

Blog

Medicines360 Statement on Title X Rule Change

As the leading nonprofit pharmaceutical company addressing women’s most pressing health needs, Medicines360 has continuously and strongly opposed the new rule restricting Title X-funded clinics from providing patients with medically accurate and comprehensive health information. Our concerns about this rule’s impact on the availability, accessibility and affordability of quality women’s health and family planning services […]

Read More >
Blog

AVIBELA™ Launches in Zambia

Medicines360 is excited to announce that Avibela™, our 52 mg levonorgestrel intrauterine device (IUD), has launched in Zambia! AVIBELA is the first hormonal IUD registered in Zambia. AVIBELA is not indicated for use in the United States. Through the global FP2020 initiative, the Zambian government has committed to improving sustainable access to family planning. In alignment […]

Read More >
Blog

Medicines360 Announces Collaborative Research to Increase LARC Access in FQHCs

Federally Qualified Health Centers (FQHCs) are community-based providers that exist to meet patients where they live and provide the primary care services they need. With approximately 12,000 service delivery sites located across the country. FQHCs serve a large number of both insured and uninsured patients. FQHCs have sliding fee scales for uninsured patients to make […]

Read More >

FEATURED UPDATES

News

International Women’s Day at Direct Relief International

SANTA BARBARA INDEPENDENT – Direct Relief’s Kirchmaier Volunteer Center was standing room only Friday morning, March 8, as more than 150 people gathered in honor of International Women’s Day to celebrate achievements and acknowledge remaining hurdles, including the lack of global access to affordable maternal health care. This year’s theme was “balance for better — […]

Read More >
Press Releases

Medicines360, Afaxys Partner to Expand Public Health Access to LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg

Strategic alliance will increase engagement with U.S. public health clinics and their patients about hormonal IUDs (long-acting reversible contraceptives, or LARCs) SAN FRANCISCO and CHARLESTON, S.C. – Medicines360 and Afaxys Pharma, LLC, two mission-driven, socially conscious women’s health pharmaceutical companies, today announced their collaboration to promote Medicines360’s intrauterine system (IUS), LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg, which is […]

Read More >
News

Medicines360 Expands Access To Contraception In Africa

FORBES – Medicines360, the non-profit pharmaceutical company behind the hormonal IUD Liletta, is on a mission to increase women’s access to reproductive care around the world. This month, the female-led company announced the launch of Avibela, a hormonal IUD, in Madagascar.

Read More >